Defined Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,199
Closed -$265K 111
2025
Q4
$265K Sell
5,199
-797
-13% -$40.8K 0.15% 101
2025
Q3
$333K Sell
5,996
-1,282
-18% -$75K 0.19% 89
2025
Q2
$502K Buy
7,278
+785
+12% +$53.4K 0.31% 76
2025
Q1
$451K Sell
6,493
-27
-0.4% -$2.23K 0.3% 77
2024
Q4
$561K Sell
6,520
-16
-0.2% -$1.73K 0.37% 60
2024
Q3
$778K Buy
6,536
+21
+0.3% +$2.8K 0.51% 50
2024
Q2
$930K Buy
6,515
+66
+1% +$8.75K 0.65% 42
2024
Q1
$828K Sell
6,449
-43
-0.7% -$5.12K 0.59% 45
2023
Q4
$672K Buy
6,492
+106
+2% +$10.5K 0.51% 50
2023
Q3
$581K Sell
6,386
-204
-3% -$18K 0.5% 54
2023
Q2
$533K Buy
6,590
+10
+0.2% +$817 0.45% 57
2023
Q1
$524K Hold
6,580
0.49% 52
2022
Q4
$445K Buy
6,580
+260
+4% +$15.2K 0.42% 66
2022
Q3
$315K Buy
6,320
+70
+1% +$3.75K 0.34% 67
2022
Q2
$348K Sell
6,250
-100
-2% -$5.55K 0.36% 67
2022
Q1
$353K Hold
6,350
0.31% 72
2021
Q4
$356K Hold
6,350
0.29% 71
2021
Q3
$305K Hold
6,350
0.27% 79
2021
Q2
$266K Hold
6,350
0.24% 83
2021
Q1
$214K Hold
6,350
0.2% 88
2020
Q4
$222K Buy
+6,350
New +$219K 0.22% 82

Other funds holding NVO

Defined Wealth Management's NVO Position: Q1 2026 in Review

Defined Wealth Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 5,199 shares — an estimated $265K sold.

Defined Wealth Management first reported a position in NVO in Q4 2020 and held it in 21 quarters. The position peaked at $930K in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Defined Wealth Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Defined Wealth Management sold 5,199 Novo Nordisk shares in Q1 2026, an estimated $265K.
  • Defined Wealth Management first reported a position in Novo Nordisk in Q4 2020 and held it in 21 quarters.
  • Defined Wealth Management's Novo Nordisk position peaked at $930K in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Defined Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.